logo-loader

Silence Therapeutics continuing to make strong progress on drug pipeline

Published: 23:54 07 Sep 2017 AEST

David Ellam, CFO for Silence Therapeutics PLC (LON:SLN) runs Proactive through the firm's results and highlights for the half year to June 2017.

Ellam says they're continuing to make good progress on their drug pipeline with plans to file their first GalNAc IND application by the end of next year.

He says they're very excited by the state of the industry as a whole.

''It's gone from being a little bit quiet for a little while to this whole new therapeutic modality ... and hopefully there will be a number of drugs available - new drugs for patients, often in areas of high unmet need and that's certainly where we're looking to focus our efforts''.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

5 hours, 43 minutes ago